Tumor Mutation Equipment
-
Manufactured by LGC SeraCarebased in USA
The Seraseq Tumor Mutation DNA Mix v2 (AF7) HC is a multiplexed mixture of actionable biosynthetic DNA targets precisely blended with a single, well-characterized genomic background. This product is produced under rigorous design control and manufacturing practices to an allelic frequency of 7%, and is offered in a high concentration (HC) ...
-
Manufactured by Tempusbased in USA
648 gene panel + Whole transcriptome RNA sequencing with validated fusion detection, Enriched for clinically relevant genes and genes of emerging clinical relevance, Immunotherapy Metrics: MSI Status, Tumor Mutational Burden (TMB), IHC Options: Mismatch Repair (MMR), PD-L1 (22C3, SP142, and 28-8 clones), Available Add-on Tests: Tumor ...
-
based in DENMARK
PIONEER is our proprietary AI platform for the rapid discovery and design of patient-specific neoepitopes used to derive immuno-oncology therapies. It has been shown that neoepitopes, which arise from patient-specific tumor mutations, play a critical role in T-cell mediated antitumor immune ...
-
Manufactured by Rubius Therapeutics, Inc.based in USA
to activate and expand NK cells. It is expected to produce a broad and potent anti-tumor T cell response, an innate immune response and have anti-tumor activity in those tumor types with known sensitivity to T cell killing, including tumor types with high mutational burden, PD-L1 expression and prior activity of ...
-
based in USA
Our DecisionDx-UMSeq is a 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma. Researchers believe that identifying mutations in tumor genes may someday help guide treatment decisions. Because the amount of tumor biopsy tissue is limited, it is important to gain as much ...
-
Manufactured by Elicio Therapeuticsbased in USA
ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled cell division during tumor growth.4 Mutations in the p53 protein lead to uncontrolled ...
-
Manufactured by Elicio Therapeuticsbased in USA
, including 40% in melanoma, 9% in colorectal cancer (CRC), and 2% in lung cancer. High levels of BRAF protein expression in these tumors suggest susceptibility to T cells targeting the mutation.3 Previous research has shown a durable complete response through transfer of tumor-infiltrating lymphocytes recognizing mutated BRAF.3 ...
-
Manufactured by Singleron Biotechnologies GmbHbased in GERMANY
FocuSCOPE is a high-throughput single cell multi-omics sequencing solution that can detect both genetic variants and transcriptome from the same single cells. Thus, FocuSCOPE® provided a tool to decipher the connection between genotype and phenotype at single cell ...
-
Manufactured by Takeda Pharmaceutical Company Limitedbased in JAPAN
. The recognition mechanism is not MHC restricted and not dependent on a single antigen. Gamma delta T cells act as orchestrators of an immune response. Modulation of these cells in situ therefore provides the potential to increase immunogenicity even in tumours with low mutational load which have proven challenging with other immunotherapies. ...
-
Manufactured by MedGenome Inc.based in USA
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the ...
-
Manufactured by Sysmex Partec GmbHbased in GERMANY
Highly sensitive down to 0.06 % MAF, Able to detect 6 MM with 95 % confidence across all mutations (absolute quantification), High flexibility of between 2-16 samples/run, Fast TAT (2 days), Convenient software. Plasma-SeqSensei (PSS) BC RUO Kit allows for the highly sensitive and specific detection of mutations in circulating tumour DNA ...
-
Manufactured by EntroGen, Inc.based in USA
-EGFR monoclonal antibody therapy (e.g. cetuximab, panitumumab and erlotnib) should be screened for KRAS mutations. Recent studies have also shown that not all mCRC patients with wild-type KRAS tumors respond to anti-EGFR therapy. ...
-
Manufactured by BridgeBio Pharma, Inc.based in USA
BridgeBio is developing SHP2 inhibitors as potentially effective additions to the therapeutic arsenal for difficult-to-treat cancers. SHP2, encoded by the PTPN11 gene, links growth factor signaling with the downstream RAS/ERK/MAPK pathway to regulate cell growth and division. Over-activity of this pathway, often driven by distinct gene ...
-
based in USA
Shifting the Paradigm of Prenatal Screening: The name of our non-invasive prenatal test (NIPT) is appropriately called “UNITY” as it brings together fetal screening for aneuploidies and recessive conditions. It also represents uniting pregnant patients in more equitable ...
-
Manufactured by Therawisbased in GERMANY
Oncosome.HER2 is a liquid biopsy diagnostic for the detection of HER2 in blood to identify patients eligible for HER2 targeted therapy. Oncosome.HER2 would address an high unmet medical ...
-
Manufactured by Cellesce Ltdbased in UNITED KINGDOM
Organoids are derived from biopsies and tissues sampled from patients or subjects (usually termed Patient-Derived Organoids, or PDOs). PDOs are self-organising cell structures that mimic the tissue or organ from which they are derived – they are often termed ‘mini-organs’. ...
-
Manufactured by EntroGen, Inc.based in USA
The KRAS gene encodes a small GTPase that plays a key role in transducing signals from the epidermal growth factor receptor (EGFR) to downstream effectors. KRAS mutations have been commonly found in several types of human malignancies, such as metastatic colorectal cancer (mCRC), lung adenocarcinoma and thyroid cancer. The most common ...
-
Manufactured by OncoDNA S.A.based in BELGIUM
Oncodeep® is a comprehensive biomarker test designed to guide treatment of advanced, metastatic solid tumors. When your patients are diagnosed with a rare cancer type or an aggressive cancer, when chemotherapy doesn't work or when cancer comes back, OncoDEEP® can provide you with clear clinical guidance. Starting from a small ...
-
by Natera, Inc.based in USA
Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer, with broad utility for cancer ...
-
by CDR-Lifebased in SWITZERLAND
a series of highly cancer-targeted and drug-based immunotherapies against intracellular tumor antigens for treatment of a variety of solid tumor malignancies. In addition, the company has a superior trispecific BCMA therapy positioned for partnering as well as a therapeutic antibody fragment for treatment of a blinding retinal disease, which is ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you